Bayer stock
Price history
+104.12% over the period1 year: from €27.94 (November 17, 2025) to €57.04 (November 16, 2026), +104.12%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | €57.04 |
| October 30, 2026 | €50.58 |
| September 30, 2026 | €47.95 |
| August 31, 2026 | €49.04 |
| July 31, 2026 | €48.05 |
| June 30, 2026 | €48.41 |
| May 29, 2026 | €36.53 |
| April 30, 2026 | €38.05 |
| March 31, 2026 | €39.38 |
| February 27, 2026 | €42.01 |
| January 30, 2026 | €44.56 |
| December 30, 2025 | €37.01 |
| November 28, 2025 | €30.49 |
| November 17, 2025 | €27.94 |
At a glance
The company
Life science company producing pharmaceuticals, consumer health products, and crop protection solutions across multiple therapeutic areas and global markets
Latest results
Quarter to September 30, 2026 · EPS €0.31 (estimate €0.44)
TickerLandia's take on Bayer
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−1.38% from the 52-week high
Analysts · 18 analysts
Average target€60.11+5.38% vs. price
Buy 13 · Hold 4 · Sell 1 · Buy
TickerLandia Fingerprint: Bayer
Compared with similar companies: very low profitability, very strong momentum, and very low growth.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricevery low14
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 11.7 23 EV/EBITDA 7.81 14 Price/book 1.90 15 Price/sales 1.21 6 Profitabilityvery low5
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 59.4% 6 Net margin −3.2% 6 ROE −4.6% 6 ROA 4.3% 2 Operating margin 16.5% 6 Earnings stabilitylow24
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 4.6% 46 Loss-making yearscounts in reverse: lower means more earnings stability 3 of 5 annual reports 2 Growthvery low14
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) −3.51% 10 Revenue growth (year over year) +4.10% 18 Financial strengthvery low17
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 1.35 42 Net debt/EBITDAcounts in reverse: lower means more financial strength 3.48 6 Interest coverage 2.65 6 Debt/equitycounts in reverse: lower means more financial strength 1.34 15 Dividendaverage47
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 27 years 50 Payout ratiopays out more than its earnings 162.2% 90 Dividend yield 0.2% 2 Market momentumvery strong94
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +15.62% 90 1-year return +88.81% 97 Relative strength (6 months) +34.31% 94 Distance from 200-day average +28.17% 95 Riskhigh66
How much the price swings.
Metric Value Position in group Volatility (60 days) 31.7% 66 Beta (1 year) 0.86 60 Maximum drawdown (12 months) 30.9% 71
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Bayer is cheaper than similar companies
Bayer's Forward P/E: 11.7, −10% against the median of a group of 10 similar companies (13.1).
Compared with 10 similar companies
| Metric | Bayer | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 11.7 | Middle | |
| Operating margin | 16.5% | Low | |
| ROE | -4.6% | Low | |
| Debt/equity | 1.34 | High | |
| Price/book | 1.90 | Low |
Grey band: the middle half of the group; tick: the median; dot: Bayer. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€10.05B
Latest quarter · Q3 2026
Net income
-€672M
Latest quarter · Q3 2026
Quarterly net margin
-6.7%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- €55.53B
- EPS
- -€1.47
- Volume
- 1.89M
- Daily trading
- €146.18M
- Dividend yield
- 0.19%
- Last ex-dividend on April 27, 2026
How Bayer is changing
All resultsRevenue grew 1.9% a year on average over the last 5 years
Operating margin fell from 18.0% to 11.2%
Revenue has fallen for 3 fiscal years in a row
Returns
Bayer returns with dividends
€1,000 invested in Bayer 5 years ago, on November 16, 2021, would be worth €1,240 today with dividends reinvested: +23.95% in total, +4.39% per year. On price alone it would be €1,138 (+13.81%).
| Period | Bayer | DAX | €1,000 becomes |
|---|---|---|---|
| 1 month | +28.30% | +5.90% | €1,283 |
| 6 months | +51.26% | +11.69% | €1,513 |
| Year to date | +54.12% | +9.23% | €1,541 |
| 1 year | +104.70% | +13.39% | €2,047 |
| 3 years | +42.13% | +69.45% | €1,421 |
| 5 years | +23.95% | +64.64% | €1,240 |
| 10 years | −16.77% | +150.85% | €832 |
Over the last 6 months it has done better than 75% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. DAX: with dividends. Calculate your investment
The chart in detail
Bayer: technical analysis
Bayer is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 60.4% below its all-time closing high (€143.87, April 10, 2015).
- Trend
- Upward
- RSI (14 sessions)
- 76
- Above 70: a strong rise in a short time
- vs 200-session average
- +29.18%
Active signals
RSI above 70: the stock has risen a lot in a short time.
since November 3, 2026
Support and resistance
Price areas where Bayer has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price€57.04
- Support€50.14−12.10%5 touches, last on September 14, 2026
- Support€47.20−17.26%3 touches, last on September 18, 2026
- Support€45.66−19.95%2 touches, last on October 15, 2026
Volatility and risk
Over the last year it has moved roughly in line with the DAX.
- Beta (1 year) vs DAX
- 0.84
- Volatility (60 sessions, annualised)
- 31.7%
- Largest fall in the last year
- −30.85%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Bayer: seasonality
Average monthly price change over 30 years
Over the last 30 years, the strongest month for Bayer has been April: +3.24% on average, positive in 17 years out of 30. The weakest has been August: −3.08% on average, positive in 12 years out of 30. November, the current month, has been positive in 19 years out of 29 (+3.15% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.77% | +0.71% | 17 of 30 |
| February | −0.81% | −1.07% | 13 of 30 |
| March | +0.14% | +0.52% | 15 of 30 |
| April | +3.24% | +1.53% | 17 of 30 |
| May | −0.41% | +0.23% | 15 of 30 |
| June | +1.85% | +0.19% | 15 of 30 |
| July | +0.68% | +1.51% | 19 of 30 |
| August | −3.08% | −1.89% | 12 of 30 |
| September | −1.85% | −3.78% | 12 of 30 |
| October | +0.21% | +2.69% | 19 of 30 |
| November | +3.15% | +4.35% | 19 of 29 |
| December | +2.42% | +3.02% | 18 of 29 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Bayer and its competitors
Known for prescription medicines in cardiology and women's health, contrast agents for diagnostic imaging, and over-the-counter products for self-medication, Bayer also sells crop protection products, seeds and digital farming solutions. Its Pharmaceuticals, Consumer Health and Crop Science segments reach customers through wholesalers, pharmacies, supermarkets, online and other retailers, and hospitals, while farmers are supplied directly. The company operates in Europe, Germany, Switzerland, North America, the United States, Asia Pacific, China, Latin America, Brazil, Africa and the Middle East.
- Headquarters
- Leverkusen, Germany
- Employees
- 87,775
- Founded
- 1863
- Chief executive
- William Anderson
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| BayerBAYN | $61.37B | 16.5% | — | +51.26% |
| GSKGSK | $101.36B | 30.5% | 17.9 | +3.57% |
| SanofiSAN | $116.24B | 22.3% | 25.3 | +18.71% |
| Novo NordiskNOVO.B | $181.48B | 50.8% | 10.9 | −3.84% |
| OrionORNAV | $15.93B | 38.1% | 22.0 | +52.14% |
| AstraZenecaAZN | $286.82B | 25.8% | 26.5 | +2.92% |
Same industry or related industries, similar size. Compare Bayer with its competitors · Full profile
